• CNV-Seq

    Clinical indications

    Postnatal

    Children or adults with unexplained disease symptoms (Peripheral blood DNA) Prenatal

    Prenatal

    Miscarriage products of conceptions (chorionic villus DNA)

    Fetal ultrasound structural abnormalities (amniocyte DNA)

    High risk pregnancies (advanced maternal age, soft ultrasound marker)

    Technology

    Wet lab

    Patent PCR-free library construction technology

    Low input: 10-50ng DNA

    Detection of aneuploidy, large fragment deletion/duplication, whole genome CNVs (>100kb) chromosome mosaicism (>10%)

    Dry lab (Bioinformatics)

    CNV analysis system

    Case sharing – apoblema testing

    Clinical information:

    31 yrs, induced labor one time, a biochemical pregnancy, six times of embryo arrest. She did such test at 7+3 weeks, no fetal buds or fetal heart.

    Test results:

    seq [hg19] dup(2)(q36.1q37.3)

    chr2:g. 224740001_243020000dup

    seq [hg19] del(8)(q24.23q24.3)

    chr8:g. 138800001_146300000del


    CNV-seq identified terminal deletion/duplication events at the end of chromosomes 2 and 8, indicating an balanced translocation.

    Follow up FISH verified that the husband had t(2;8)(q36.1;q24.23) balanced translocation. The couple choose PGT and they successfully achieved a healthy baby.

    Why choose Berry Genomics for CNV-Seq

    Low cost

    Integrated professional teams for sequencing, data analysis and reporting

    Fast turnaround time

    Reliable and accurate results equivalent to current array CGH and SNP arrays

    The clinical significance of CNV-Seq

    Can detect aneuploidy, CNVs (resolution 0.1Mb) and mosaicism (resolution) that are associated with known chromosome disease syndromes

    Applicable to genetic diagnosis of preconception, prenatal and postnatal samples

    Can identify a genetic cause of miscarriage samples

    Reliable results can be obtained from rare samples or samples with low amounts of DNA


    【网站舆图】【sitemap】